New treatment modalities for vitiligo: Focus on topical immunomodulators

Drugs

Volumn 65, Issue 4, 2005, Pages 447-459

  Kostovic, Kresimir ^a   Pasic, Aida ^a  

^a UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

[No Author keywords available]

Indexed keywords

CALCINEURIN INHIBITOR; CALCIPOTRIOL; CLOBETASOL; CORTICOSTEROID; CYCLOSPORIN; DERMATOLOGICAL AGENT; HYDROCORTISONE; IMMUNOMODULATING AGENT; MACROLIDE; PIMECROLIMUS; PSEUDOCATALASE; TACROLIMUS; UNCLASSIFIED DRUG;

ACNE; ATOPIC DERMATITIS; AUTOIMMUNITY; BURNING SENSATION; CATARACT; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG ABSORPTION; DRUG MECHANISM; DRUG MONITORING; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG TOLERABILITY; EYELID DISEASE; GLAUCOMA; HUMAN; MONOTHERAPY; OPPORTUNISTIC INFECTION; PATHOGENESIS; PERIORAL DERMATITIS; PHOTOTHERAPY; PSORIASIS; PUVA; REVIEW; SIDE EFFECT; SKIN ATROPHY; SKIN PENETRATION; SKIN PIGMENTATION; SYSTEMATIC REVIEW; T LYMPHOCYTE ACTIVATION; TELANGIECTASIA; TREATMENT OUTCOME; ULTRAVIOLET B RADIATION; VITILIGO;

ADMINISTRATION, TOPICAL; ADRENAL CORTEX HORMONES; CLINICAL TRIALS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; PUVA THERAPY; VITILIGO;

EID: 16344375058     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200565040-00002     Document Type: Review

References (120)

1. Kostovic K, Nola I, Bucan Z, et al. Treatment of vitiligo: current methods and new approaches. Acta Dermatovenerol Croat 2003; 11 (3): 163-70
2. Kovacs SO. Vitiligo. J Am Acad Dermatol 1998 May; 38 (5 Pt 1): 647-66
3. Mosher DB, Fitzpatrick TB, Ortonne JP, et al. Disorders of pigmentation. In: Fitzpatrick TB, Freedberg IM, editors. Fitzpatrick's dermatology in general medicine. 5th ed. New York: McGraw-Hill, Health Professions Division, 1999: 945-55
4. Mohr J. Vitiligo in a pair of monovular twins. Acta Genet Stat Med 1951; 2 (3): 252-5
5. Siemens HW. Die Zwillingspathologie der vitiligo. Acta Genet Med Gemellol (Roma) 1953; 2: 118-24
6. Majumder PP, Das DK, Li CC. A genetic model for vitiligo. Am J Hum Genet 1988 Aug; 43 (2): 119-25
7. Nath SK, Majumder PP, Nordlund JJ. Genetic epidemiology of vitiligo: multilocus recessivity crossvalidated. Am J Hum Genet 1944 Nov; 55 (5): 981-90
8. Majumder PP, Nordlund JJ, Nath SK. Pattern of familial aggregation of vitiligo. Arch Dermatol 1993 Aug; 129 (8): 994-8
9. Hafez M, Sharaf L, Abdel-Nabi SM. The genetics of vitiligo. Acta Dermatol Venereol 1983; 63 (3): 249-51
10. Schallreuter KU, Lemke R, Brandt O, et al. Vitiligo and other diseases: coexistence or true association? Hamburg study on 321 patients. Dermatology 1994; 188 (4): 269-75
11. Grimes PE, Halder RM, Jones C, et al. Autoantibodies and their clinical significance in a black vitiligo population. Arch Dermatol 1983 Apr; 119 (4): 300-3
12. Hegedüs L, Heidenheim M, Gervil M, et al. High frequency of thyroid disfunction in patients with vitiligo. Acta Derm Venereol 1994 Mar; 74 (2): 120-3
13. Shong YK, Kim JA. Vitiligo in autoimmune thyroid disease. Thyroidology 1991 May; 3 (2): 89-91
14. Gould IM, Gray RS, Urbaniak SJ, et al. Vitiligo in diabetes mellitus. Br J Dermatol 1985 Aug; 113 (2): 153-5
15. Mulligan TM, Sowers JR. Hyperpigmentation, vitiligo, and Addison's disease. Cutis 1985 Oct; 36 (4): 317-8, 322
16. Howitz J, Schwartz M. Vitiligo, achlorhydria, and pernicious anemia. Lancet 1971 Jun; I (7713): 1331-4
17. Abraham Z, Rozenbaum M, Glück Z, et al. Vitiligo, rheumatoid arthritis and pernicious anemia. J Dermatol 1993 Jul; 20 (7): 418-23
18. Njoo MD, Westerhof W. Vitiligo: pathogenesis and treatment. Am J Clin Dermatol 2001; 2 (3): 167-81
19. Hertz KC, Gazze LA, Kirckpatrick CH, et al. Autoimmune vitiligo: detection of antibodies to melanin-producing cells. N Engl J Med 1977 Sep; 297 (12): 634-7
20. Yu HS, Kao CH, Yu CL. Coexistence and relationship of antikeratinocyte and antimelanocyte antibodies in patients with non-segmental-type vitiligo. J Invest Dermatol 1993 Jun; 100 (6): 823-8
21. Cui J, Arita Y, Bystryn JP. Characterization of vitiligo antigens. Pigment Cell Res 1995 Feb; 8 (1): 53-9
22. Cui J, Harning R, Henn M, et al. Identification of pigment cell antigens defined by vitiligo antibodies. J Invest Dermatol 1992 Feb; 98 (2): 162-5
23. Song YH, Connor E, Li Y, et al. The role of tyrosinase in autoimmune vitiligo. Lancet 1994 Oct; 344 (8929): 1049-59
24. Baharav E, Merimski O, Shoenfeld Y, et al. Tyrosinase as an autoantigen in patients with vitiligo. Clin Exp Immunol 1996 Jul; 105 (1): 84-8
25. Okamoto T, Irie RF, Fujii S, et al. Anti-tyrosinase-related protein-2 immune response in vitiligo and melanoma patients receiving active-specific immunotherapy. J Invest Dermatol 1998 Dec; 111 (6): 1034-9
26. Kemp EH, Waterman EA, Gawkrodger DJ, et al. Autoantibodies to tyrosinase-related protein-1 detected in the sera of vitiligo patients using a quantitative radiobinding assay. Br J Dermatol 1998 Nov; 139 (5): 798-805
27. Harning R, Cui J, Bystryn JC. Relation between the incidence and level of pigment cell antibodies and disease activity in vitiligo. J Invest Dermatol 1991 Dec; 97 (6): 1078-80
28. Naughton GK, Reggiardo MD, Bystryn JC. Correlation between vitiligo antibodies and extent of depigmentation in vitiligo. J Am Acad Dermatol 1986 Nov; 15 (5 Pt 1): 978-81
29. Badri AM, Todd PM, Garioch JJ, et al. An immunohistological study of cutaneous lymphocytes in vitiligo. J Pathol 1993 Jun; 170 (2): 149-55
30. Ahn SK, Choi EH, Lee SH, et al. Immunohistochemical studies from vitiligo: comparison between active and inactive lesions. Yonsei Med J 1994 Dec; 35 (4): 404-10
31. Le Poole IC, van den Wijngaard RMJGJ, Westerhof W, et al. Presence or absence of melanocytes in vitiligo lesions: an immunohistochemical investigation. J Invest Dermatol 1993 Jun; 100 (6): 816-22
32. Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res 2003 Apr; 16 (2): 90-100
33. Abdel-Naser MB, Kriiger-Krasagakes S, Krasagakis K, et al. Further evidence for involvement of both cell mediated and humoral immunity in generalized vitiligo. Pigment Cell Res 1994 Feb; 7 (1): 1-8
34. Honda Y, Okubo Y, Koga M. Relationship between levels of soluble interleukin-2 receptor and the types and activity of vitiligo. J Dermatol 1997 Sep; 24 (9): 561-3
35. Yeo UC, Yang YS, Park KB, et al. Serum concentration of the soluble interleukin-2 receptor in vitiligo patients. J Dermatol Sci 1999 Apr; 19 (3): 182-8
36. Hara M, Toyoda M, Yaar M, et al. Innervation of melanocytes in human skin. J Exp Med 1996 Oct; 184 (4): 1385-95
37. Gokhale BB, Mehta LN. Histopathology of vitiliginous skin. Int J Dermatol 1983 Oct; 22 (8): 477-80
38. Al'Abadie MS, Warren MA, Beehen SS, et al. Morphologic observations on the dermal nerves in vitiligo: an ultrastructural study. Int J Dermatol 1995 Dec; 34 (12): 837-40
39. Liu PY, Bondesson L, Lontz W, et al. The occurrence of cutaneous nerve endings and neuropeptides in vitiligo vulgaris: a case-control study. Arch Dermatol Res 1996 Oct; 288 (11): 670-5
40. Al'Abadie MS, Senior HJ, Bleehen SS, et al. Neuropeptide and neuronal marker studies in vitiligo. Br J Dermatol 1994 Aug; 131 (2): 160-5
41. Mozzanica N, Villa ML, Foppa S, et al. Plasma α-melanocyte- stimulating hormone, β-endorphin, met-enkephalin, and natural killer cell activity in vitiligo. J Am Acad Dermatol 1992 May; 26 (5 Pt 1): 693-700
42. Caixia T, Daming Z, Xiran L. Levels of beta-endorphin in the plasma and skin tissue fluids of patients with vitiligo. J Dermatol Sci 2001 May; 26 (1): 62-6
43. Salzer BA, Schallreuter KU. Investigation of the personality structure in patients with vitiligo and a possible association with impaired catecholamine metabolism. Dermatology 1995; 190 (2): 109-15
44. Morrone A, Picardo M, de Luca C, et al. Catecholamines and vitiligo. Pigment Cell Res 1992 Mar; 5 (2): 65-9
45. Cucchi ML, Frattini P, Santagostino G, et al. Catecholamines increase in the urine of non-segmental vitiligo especially during its active phase. Pigment Cell Res 2003 Apr; 16 (2): 111-6
46. Taneja A. Treatment of vitiligo. J Dermatol Treat 2002; 13: 19-25
47. Schallreuter KU, Wood JM, Ziegler I, et al. Defective tetrahydrobiopterin and catecholamine biosynthesis in the depigmentation disorder vitiligo. Biochem Biophys Acta 1994; 1226: 181-92
48. Schallreuter KU, Wood JM, Pittelkow MR, et al. Regulation of melanin biosynthesis in the human epidermis by tetrahydrobiopterin. Science 1994 Mar; 263 (5152): 1444-6
49. Schallreuter KU, Wood JM, Berger J. Low catalase levels in the epidermis of patients with vitiligo. J Invest Dermatol 1991 Dec; 97 (6): 1081-5
50. Schallreuter KU. Successful treatment of oxidative stress in vitiligo. Skin Pharmacol Appl Skin Physiol 1999; 12 (3): 132-8
51. Bos JD, Meinardi MM. The 500 Dalton rule for the skin penetration of chemical compounds and drugs. Exp Dermatol 2000 Jun; 9 (3): 165-9
52. Ruzicka T, Bieber T, Schöpf E, et al. A short-term trial of tacrolimus ointment for atopic dermatitis: European Tacrolimus Multicenter Atopic Dermatitis Study Group. N Engl J Med 1997 Sep; 337: 816-21
53. Hanifin JM, Ling MR, Langley R, et al. Tacrolimus ointment for the treatment of atopic dermatitis in adult patients: part I, efficacy. J Am Acad Dermatol 2001 Jan; 44 (1 Suppl.): S28-38
54. Boguniewicz M, Fiedler VC, Raimer S, et al. A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children: Pediatric Tacrolimus Study Group. J Allergy Clin Immunol 1998 Oct; 102 (4 Pt 1): 637-44
55. Paller A, Eichenfield LF, Leung DYM, et al. A 12-week study of tacrolimus ointment for the treatment of atopic dermatitis in pediatric patients. J Am Acad Dermatol 2001 Jan; 44 (1 Suppl): S47-57
56. Luger T, Van Leent EJ, Graeber M, et al. SDZ ASM 981: an emerging safe and effective treatment for atopic dermatitis. Br J Dermatol 2001 Apr; 144 (4): 788-94
57. Van Leent EJ, Graeber M, Thurston M, et al. Effectiveness of the ascomycin macrolactam SDZ ASM 981 in the topical treatment of atopic dermatitis. Arch Dermatol 1998 Jul; 134 (7): 805-9
58. Nghiem P, Pearson G, Langley RG. Tacrolimus and pimecrolimus: from clever prokaryotes to inhibiting cal and treating atopic dermatitis. J Am Acad Dermatol 2002 Feb; 46 (2): 228-41
59. Marsland AM, Griffiths CE. The macrolide immunosuppressants in dermatology: mechanisms of action. Eur J Dermatol 2002; 12 (6): 618-22
60. Bornhövd EC, Burgdorf WH, Wollenberg A. Immunomodulatory macrolactams for topical treatment of inflammatory diseases. Curr Opin Investig Drugs 2002 May; 3 (5): 708-12
61. Paul C, Graeber M, Stuetz A. Ascomycins: promising agents for the treatment of inflammatory skin diseases. Expert Opin Investig Drugs 2000 Jan; 9 (1): 69-77
62. Lawrence ID. Tacrolimus (FK506): experience in dermatology. Dermatol Ther 1998; 5: 74-84
63. Cheer SM, Plosker GL. Tacrolimus ointment: a review of its therapeutic potential as a topical therapy in atopic dermatitis. Am J Clin Dermatol 2001; 2 (6): 389-406
64. Gupta AK, Chow M. Pimecrolimus: a review. J Eur Acad Dermatol Venereol 2003 Sep; 17 (5): 493-503
65. Zuberbier T, Chong SU, Grunow K, et al. The ascomycin macrolactam pimecrolimus (Elidel, SDZ ASM 981) is a potent inhibitor of mediator release from human dermal mast cells and peripheral blood basophils. J Allergy Clin Immunol 2001 Aug; 108 (2 Pt 1): 275-80
66. de Paulis A, Stellato C, Cirillo R, et al. Anti-inflammatory effect of FK-506 on human skin mast cells. J Invest Dermatol 1992 Dec; 99 (6): 723-8
67. Wollenberg A, Sharma S, von Bubnoff D, et al. Topical tacrolimus (FK506) leads to profound phenotypic and functional alterations of epidermal antigen-presenting dendritic cells in atopic dermatitis. J Allergy Clin Immunol 2001 Mar; 107 (3): 519-25
68. Reitamo S, Rissanen J, Remitz A, et al. Tacrolimus ointment does not affect collagen synthesis: results of a single-center randomized trial. J Invest Dermatol 1998 Sep; 111 (3): 396-8
69. Queille-Roussel C, Paul C, Duteil L, et al. The new topical ascomycin derivative SDZ ASM 981 does not induce skin atrophy when applied to normal skin for 4 weeks: a randomized, double-blind controlled study. Br J Dermatol 2001 Mar; 144 (3): 507-13
70. Ogg GS, Rod Dunbar P, Romero P, et al. High frequency of skin-homing melanocyte-specific cytotoxic T lymphocytes in autoimmune vitiligo. J Exp Med 1998 Sep; 188 (6): 1203-8
71. Le Poole IC, van den Wijngaard RM, Westerhof W, et al. Presence of T cells and macrophages in inflammatory vitiligo skin parallels melanocyte disappearance. Am J Pathol 1996 Apr; 148 (4): 1219-28
72. Badri AM, Foulis AK, Todd PM, et al. Abnormal expression of MHC class II and ICAM-1 by melanocytes in vitiligo. J Pathol 1993 Feb; 169 (2): 203-6
73. van den Wijngaard R, Wankowicz-Kalinska A, Le Poole C, et al. Local immune response in skin of generalized vitiligo patients: destruction of melanocytes is associated with the prominent presence of CLA+T cells at the perilesional site. Lab Invest 2000 Aug; 80 (8): 1299-309
74. Yohn JJ, Critelli M, Lyons MB, et al. Modulation of melanocyte intercellular adhesion molecule-1 by immune cytokines. J Invest Dermatol 1990 Aug; 95 (2): 233-7
75. Caixia T, Hongwen F, Xiran L. Levels of soluble interleukin-2 receptor in the sera and skin tissue fluids of patients with vitiligo. J Dermatol Sci 1999 Sep; 21 (1): 59-62
76. Rubin LA, Nelson DL. The soluble interleukin-2 receptor: biology, function, and clinical application. Ann Intern Med 1990 Oct; 113 (8): 619-27
77. Mahmoud F, Abul H, al-Saleh Q, et al. Peripheral T-cell activation in non-segmental vitiligo. J Dermatol 1998 Oct; 25 (10): 637-40
78. Abdel-Naser MB, Ludwig WD, Gollnick H, et al. Nonsegmental vitiligo: decrease of the CD45RA+T-cell subset an evidence for peripheral T-cell activation. Int J Dermatol 1992 May; 31 (5): 321-6
79. Mahmoud F, Abul H, Haines D, et al. Decreased total numbers of peripheral blood lymphocytes with elevated percentages of CD4+CD45RO+ and CD4+CD25+ of T helper cells in nonsegmental vitiligo. J Dermatol 2002 Feb; 29 (2): 68-73
80. Smith DA, Tofte SJ, Hanifin JM. Repigmentation of vitiligo with topical tacrolimus. Dermatology 2002; 205 (3): 301-3
81. Mayoral FA, Gonzalez C, Shah NS, et al. Repigmentation of vitiligo with pimecrolimus cream: a case report. Dermatology 2003; 207 (3); 322-3
82. Travis LB, Weinberg JM, Silverberg NB. Successful treatment of vitiligo with 0.1% tacrolimus ointment. Arch Dermatol 2003 May; 139 (5): 571-4
83. Grimes PE, Soriano T, Dytoc MT. Topical tacrolimus for repigmentation of vitiligo. J Am Acad Dermatol 2002 Nov; 47 (5): 789-91
84. Tanghetti EA. Tacrolimus ointment 0.1% produces repigmentation in patients with vitiligo: results of a prospective patient series. Cutis 2003 Feb; 71 (2): 158-62
85. Lepe V, Moncada B, Castanedo-Cazares JP. A double-blind randomized trial of 0.1% tacrolimus vs 0.05% clobetasol for the treatment of childhood vitiligo. Arch Dermatol 2003 May; 139 (5): 581-5
86. Grimes PE, Morris R, Avaniss-Aghajani E, et al. Topical tacrolimus therapy for vitiligo: therapeutic responses and skin messenger RNA expression of proinflammatory cytokines. J Am Acad Dermatol 2004 Jul; 51 (1 Pt 1): 52-61
87. Njoo MD, Spuls PI, Bos JD, et al. Nonsurgical repigmentation therapies in vitiligo: meta-analysis of the literature. Arch Dermatol 1998 Dec; 134 (12): 1532-40
88. Reitamo S, Remitz A, Kyllönen H, et al. Topical noncorticosteroid immunomodulation in the treatment of atopic dermatitis. Am J Clin Dermatol 2002; 3 (6): 381-8
89. Wellington K, Jarvis B. Topical pimecrolimus: a review of its clinical potential in the management of atopic dermatitis. Drugs 2002; 62 (5): 817-40
90. Kang S, Lucky AW, Pariser D, et al. Tacrolimus Ointment Study Group. Long-term safety and efficacy of tacrolimus ointment for the treatment of atopic dermatitis in children. J Am Acad Dermatol 2001; 44 (1 Suppl.): S58-64
91. Fleischer Jr AB, Ling M, Eichenfield L, et al. Tacrolimus ointment for the treatment of atopic dermatitis is not associated with and increase in cutaneous infections. J Am Acad Dermatol 2002 Oct; 47 (4): 562-70
92. Wahn U, Bos JD, Goodfield M, et al. Efficacy and safety of pimecrolimus cream in the long-term management of atopic dermatitis in children. Pediatrics 2002 Jul; 110 (1 Pt 1): e2
93. Kapp A, Papp K, Bingham A, et al. Long-term management of atopic dermatitis in infants with topical pimecrolimus, a non-steroid anti-inflammatory drug. J Allergy Clin Immunol 2002 Aug; 110 (2): 277-84
94. Fisher DA. Adverse effects of topical corticosteroid use. West J Med 1995 Feb; 162 (2): 123-6
95. Smith EW. Four decades of topical corticosteroid assessment. Curr Probl Dermatol 1995; 22: 124-31
96. Pierard GE, Pierard-Franchimont C, Ben Mosbah T, et al. Adverse effects of topical corticosteroids. Acta Derm Venereol Suppl (Stockh) 1989; 151: 26-30
97. Hartmann A, Bröcker EB, Becker JC. Hypopigmentary skin disorders: current treatment options and future directions. Drugs 2004; 64 (1): 89-107
98. Carnahan MC, Goldstein DA. Ocular complications of topical, peri-ocular, and systemic corticosteroids. Curr Opin Ophthalmol 2000 Dec; 11 (6): 478-83
99. Freeman AK, Serle J, Van Veldhuisen P, et al. Tacrolimus ointment in the treatment of eyelid dermatitis. Cutis 2004 Apr; 73 (4): 267-71
100. Rikkers SM, Holland GN, Drayton GE, et al. Topical tacrolimus treatment of atopic eyelid disease. Am J Ophthalmol 2003 Mar; 135 (3): 297-302
101. Goldstein E, Haberman HF, Menon IA, et al. Non-psoralen treatment of vitiligo. Part I: cosmetics, systemic coloring agents, and corticosteroids. Int J Dermatol 1992 Apr; 31 (4): 229-36
102. Protopic [package insert]. Deerfield (IL): Fujisava Healthcare Inc., 2000
103. Castanedo-Cazares JP, Lepe V, Moncada B. Repigmentation of chronic vitiligo lesions by following tacrolimus plus ultraviolet-B-narrow-band. Photodermatol Photoimmunol Photomed 2003 Feb; 19 (1): 35-6
104. Kawalek AZ, Spencer JM, Phelps RG. Combined excimer laser and topical tacrolimus for the treatment of vitiligo: a pilot study. Dermatol Surg 2004 Feb; 30 (2 Pt 1): 130-5
105. Passeron T, Ostovari N, Zakaria W, et al. Topical tacrolimus and the 308-nm excimer laser: a synergistic combination for the treatment of vitiligo. Arch Dermatol 2004 Sep; 140 (9): 1065-9
106. Njoo MD, Bos JD, Westerhof W. Treatment of generalized vitiligo in children with narrow-band (TL-01) UVB radiation therapy. J Am Acad Dermatol 2000 Feb; 42 (2 Pt 1): 245-53
107. Westerhof W, Nieuweboer-Krobotova L. Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A. Arch Dermatol 1997 Dec; 133 (12): 1591-2
108. Schallreuter KU, Wood JM, Lemke KR, et al. Treatment of vitiligo with a topical application of pseudocatalase and calcium in combination with short-term UVB exposure: a case study on 33 patients. Dermatology 1995; 190 (3): 181-2
109. Schallreuter KU. Pseudocatalase in the treatment of vitiligo. In: Hann SK, Nordlund J, editors. Vitiligo: a monograph on the basic and clinical science. Pt 4. Berlin: Blackwell Science Inc., 2000
110. Patel DC, Evans AV, Hawk JL. Topical pseudocatalase mousse and narrow band UVB phototherapy is not effective for vitiligo: an open, single-centre study. Clin Exp Dermatol 2002 Nov; 27 (8): 641-4
111. Schallreuter KU, Pittelkow MR. Defective calcium uptake in keratinocyte cell cultures form vitiliginous skin. Arch Dermatol Res 1988; 280 (3): 137-9
112. 3 on epidermal melanocytes. J Cell Physiol 1988 Aug; 136 (2): 273-80
113. Nordlund JJ, Abdel-Malek ZA, Boissy RE, et al. Pigment cell biology: an historical review. J Invest Dermatol 1989 Apr; 92 (4 Suppl.): 53S-60S
114. Parsad D, Saini R, Verma N. Combination of PUVAsol and topical calcipotriol in vitiligo. Dermatology 1998; 197 (2): 167-70
115. Yalcin B, Sahin S, Bukulmez G, et al. Experience with calcipotriol as adjunctive treatment for vitiligo in patients who do not respond to PUVA alone: a preliminary study. J Am Acad Dermatol 2001 Apr; 44 (4): 634-7
116. Ermis O, Alpsoy E, Cetin L, et al. Is the efficacy of psoralen plus ultraviolet A therapy for vitiligo enhanced by concurrent topical calcipotriol? A placebo-controlled double-blind study. Br J Dermatol 2001 Sep; 145 (3): 472-5
117. Cherif F, Azaiz MI, Ben Hamida A, et al. Calcipotriol and PUVA as treatment for vitiligo. Dermatol Online J 2003 Dec; 9 (5): 4
118. Chiaverini C, Passeron T, Ortonne JP. Treatment of vitiligo by topical calcipotriol. J Eur Acad Dermatol Venereol 2002 Mar; 16 (2): 137-8
119. Köse O, Riza Gür A, Kurumlu Z, et al. Calcipotriol ointment versus clobetasol ointment in localized vitiligo: an open, comparative clinical trial. Int J Dermatol 2002 Sep; 41 (9): 616-8
120. Spencer JM, Nossa R, Ajmeri J. Treatment of vitiligo with 308-nm excimer laser: a pilot study. J Am Acad Dermatol 2002 May; 46: 727-31